U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H26NO4S
Molecular Weight 328.447
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of SUPLATAST

SMILES

CCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1

InChI

InChIKey=DYZJXZOQQRXDLE-UHFFFAOYSA-O
InChI=1S/C16H25NO4S/c1-4-20-11-14(18)12-21-15-7-5-13(6-8-15)17-16(19)9-10-22(2)3/h5-8,14,18H,4,9-12H2,1-3H3/p+1

HIDE SMILES / InChI

Molecular Formula C16H25NO4S
Molecular Weight 327.439
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including https://www.jstage.jst.go.jp/article/allergolint/54/4/54_4_533/_pdf

Suplatast is a novel immunomodulator that can adjust the imbalance in the Th1/Th2 immune response and shows clear clinical efficacy against bronchial asthma (BA). Suplatast tosilate helps to suppress the production of IgE, to block the production of cytokines and to suppress allergy-related eosinophils. Clinical studies on the efficacy of Suplatast were carried out in Japan. Suplatast showed adequate efficacy for the treatment of BA, allergic rhinitis and atopic dermatitis. Suplatast is now available for the management of BA as a controller of the Th2-dependent allergic inflammation. Suplatast tosilate is not approved in the United States, but is available in Japan as Tosilart® and IPD Capsules®. IPD-1151T (suplatast tosilate) was originated by Taiho and is being developed for the treatment of interstitial cystitis and chronic non-bacterial prostatitis as additional indications. IPD-1151T treatment for 1 year resulted in a significantly increased bladder capacity and decreased symptoms, such as urinary urgency, frequency and lower abdominal pain, in patients with nonulcerative interstitial cystitis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P05112
Gene ID: 3565.0
Gene Symbol: IL4
Target Organism: Homo sapiens (Human)
Conditions
PubMed

PubMed

TitleDatePubMed
Suplatast tosilate (IPD), a new immunoregulator, is effective in vitiligo treatment.
1998 Apr
Treatment of non-episodic angioedema associated with eosinophilia with suplatast tosilate, an anti-allergic selective Th2 cytokine inhibitor.
2014 Mar-Apr
[A case report of eosinophilic cystitis treated with oral suplatast tosilate].
2014 Sep
Patents

Patents

Sample Use Guides

IPD-1151T (suplatast tosilate) 100 mg capsules was orally administered to the patients 3 times daily for 12 weeks of treatment period.
Route of Administration: Oral
In Vitro Use Guide
In vitro, NCI-H292 cells were preincubated with suplatast tosilate (0.1-100 u/mL) 1 hour.
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:15:20 GMT 2023
Edited
by admin
on Sat Dec 16 05:15:20 GMT 2023
Record UNII
4T0HO29O56
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SUPLATAST
Common Name English
SUPLATAST ION
Common Name English
SULFONIUM, (3-((4-(3-ETHOXY-2-HYDROXYPROPOXY)PHENYL)AMINO)-3-OXOPROPYL)DIMETHYL-
Systematic Name English
SUPLATAST CATION
Common Name English
Code System Code Type Description
PUBCHEM
71774
Created by admin on Sat Dec 16 05:15:20 GMT 2023 , Edited by admin on Sat Dec 16 05:15:20 GMT 2023
PRIMARY
DRUG CENTRAL
2545
Created by admin on Sat Dec 16 05:15:20 GMT 2023 , Edited by admin on Sat Dec 16 05:15:20 GMT 2023
PRIMARY
EPA CompTox
DTXSID2045074
Created by admin on Sat Dec 16 05:15:20 GMT 2023 , Edited by admin on Sat Dec 16 05:15:20 GMT 2023
PRIMARY
WIKIPEDIA
Suplatast
Created by admin on Sat Dec 16 05:15:20 GMT 2023 , Edited by admin on Sat Dec 16 05:15:20 GMT 2023
PRIMARY
CAS
94055-75-1
Created by admin on Sat Dec 16 05:15:20 GMT 2023 , Edited by admin on Sat Dec 16 05:15:20 GMT 2023
PRIMARY
FDA UNII
4T0HO29O56
Created by admin on Sat Dec 16 05:15:20 GMT 2023 , Edited by admin on Sat Dec 16 05:15:20 GMT 2023
PRIMARY